Microvascular Complications of Diabetes Mellitus: Renal Protection Accompanies Cardiovascular Protection

American Journal of Cardiology

Volumn 102, Issue 12 SUPPL., 2008, Pages 10L-13L

  Brown, W Virgil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; FENOFIBRATE; STATIN;

ARTICLE; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MICROALBUMINURIA; MICROANGIOPATHY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL PROTECTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RISK FACTORS;

EID: 57649110072     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.068     Document Type: Article

References (32)

1. Gregg E.W., Gu Q., Cheng Y.J., Narayan K.M., and Cowie C.C. Mortality trends in men and women with diabetes, 1971-2000. Ann Intern Med 147 (2007) 149-155
2. Lipscombe L.L., and Hux E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 369 (2007) 750-756
3. National Diabetes Statistics. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm Accessed October 2007
4. Skyler J.S. Microvascular complications: retinopathy and nephropathy. Endocrinol Metab Clin North Am 30 (2001) 833-856
5. Jawa A., Kcomt J., and Fonseca V.A. Diabetic nephropathy and retinopathy. Med Clin North Am 88 (2004) 1001-1036
6. Vinik A.I., and Vinik E. The prevention of the complications of diabetes. Am J Manag Care 9 (2003) S63-S80
7. The United States Renal Data System. USRDS Annual Data Report. Bethesda, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2006. www.usrds.org/atlas.htm Accessed October 2007
8. Mogensen C.E., and Poulsen P.L. Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int Suppl 66 (2004) S40-S41
9. McCullough P.A., Jurkovitz C.T., Pergola P.E., McGill J.B., Brown W.W., Collins A.J., Chen S.C., Li S., Singh A., Norris K.C., Klag M.J., Bakris G.L., and KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Intervention Program (KEEP). Arch Intern Med 167 (2007) 1122-1129
10. Elsayed E.F., Tighiouart H., Griffith J., Kurth T., Levey A.S., Salem D., Sarnak M.J., and Weiner D.E. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 167 (2007) 1130-1136
11. Brownlee M. Banting Lecture 2004. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
12. Kaysen G.A., and Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15 (2004) 538-548
13. Misra A., Kumar S., Kishore Vikram A., and Kumar A. The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs 3 (2003) 325-338
14. 1c as markers of diabetic complications. Diabetes 48 (1999) 870-880
15. Genuth S., Sun W., Cleary P., Sell D.R., Gahms W., Malone J., Sivitz W., and Monnier V.M. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants with type 1 diabetes. Diabetes 54 (2005) 3103-3111
16. Beisswenger P.J., Makita Z., Curphey T.J., Moore L.L., Jean S., Brinck-Johnsen T., Bucala R., and Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44 (1995) 824-829
17. DeRubertis F.R., Craven P.A., and Melhem M.F. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism 56 (2007) 1256-1264
18. Son S.M. Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. Diabetes Res Clin Pract 77 suppl 1 (2007) S65-S70
19. Moorhead J.F., Chan M.K., and El-Naras M. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2 (1982) 1309-1311
20. Klein R.L., McHenry M.B., Lok K.H., Hunter S.J., Le N.A., Jenkins A.J., Zheng D., Semler A., Brown W.V., Lyons T.J., Garvey W.T., and DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in type I diabetes: associations with lipoprotein subclasses. Metabolism 53 (2004) 1296-1304
21. Kendall D.M., and Bergenstal R.M. Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care 7 (2001) S327-S343
22. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
23. Gaede P., Vedel P., Larsen N., Jensen G., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
25. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.W., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113 (2006) 2363-2372
26. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
27. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., Fonseca V., Gerstein H.C., Grundy S., Nesto R.W., et al., American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007) 114-126
28. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
29. Steiner G. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Am J Cardiol suppl xx (2008) xxx-xxx.[[this issue]]
30. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol suppl xx (2008) xxx-xxx.[[this issue]]
31. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DIAS). Am J Kidney Dis 45 (2005) 485-493
32. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al., FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861